Menu

12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga Insights 1 hour ago

Movers

Gainers Oragenics (AMEX:OGEN) stock increased by 30.2% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $1.5 million. InspireMD (NASDAQ:NSPR) shares rose 13.88%

Gainers

  • Oragenics (AMEX:OGEN) stock increased by 30.2% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $1.5 million.
  • InspireMD (NASDAQ:NSPR) shares rose 13.88% to $0.88. The company's market cap stands at $37.4 million. As per the press release, Q3 earnings came out today.
  • Instinct Bio Technical Co (NASDAQ:BIOT) stock rose 13.33% to $0.21. The company's market cap stands at $5.8 million.
  • EyePoint (NASDAQ:EYPT) shares moved upwards by 9.54% to $0.35. The company's market cap stands at $30.7 million. As per the press release, Q3 earnings came out today.
  • China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 9.52% to $2.99.
  • Can Fite Biopharma (AMEX:CANF) stock rose 9.27% to $1.61. The market value of their outstanding shares is at $3.3 million.

Losers

  • Accendra Health (NYSE:ACH) shares fell 6.2% to $0.14 during Thursday's after-market session. The company's market cap stands at $11.0 million.
  • Redhill Biopharma (NASDAQ:RDHL) stock declined by 5.23% to $0.36. The market value of their outstanding shares is at $3.2 million.
  • Lucid Diagnostics (NASDAQ:LUCD) shares declined by 5.12% to $0.4. The market value of their outstanding shares is at $72.8 million. The company's, Q3 earnings came out today.
  • Q32 Bio (NASDAQ:QTTB) stock decreased by 4.77% to $8.4. The company's market cap stands at $275.2 million.
  • Arcus Biosciences (NYSE:RCUS) stock decreased by 4.34% to $17.0. The company's market cap stands at $2.3 billion.
  • Addex Therapeutics (NASDAQ:ADXN) stock declined by 4.16% to $5.07. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Read the original